ASTX

Astex Pharmaceuticals

Stock NASDAQ – Stock Market Prices, News & Analysis

Biopharmaceutical company specialized in the discovery and development of innovative drugs primarily for cancer treatment.

$ 44.22
7.83 %

Astex Pharmaceuticals

$ 44.22
7.83 %
ASTX

Biopharmaceutical company specialized in the discovery and development of innovative drugs primarily for cancer treatment.

Price history of Astex Pharmaceuticals
Price history of Astex Pharmaceuticals

Performance & Momentum

6 Months 60.59 %
1 Year 45.89 %
3 Years 45.89 %
5 Years 45.89 %
Momentum
79

Strategic Analysis

Astex Pharmaceuticals • 2026

Astex Pharmaceuticals positions itself as an innovative player in biopharmaceuticals, specialized in the discovery and development of cutting-edge oncology treatments. Its model is based on in-depth expertise in clinical research and strategic partnerships to accelerate the market launch of its molecules.

Strengths
  • Strong specialization in oncology with a portfolio of innovative drugs
  • Robust expertise in drug discovery combined with a rigorous clinical approach
  • Growth potential supported by the favorable evolution of the healthcare and biotechnology sectors
Weaknesses
  • Dependence on clinical trial results to validate its projects
  • Exposure to regulatory risk related to the commercialization of new treatments
Momentum

The robust momentum highlights increased investor interest, supported by consistent performance over several years. This positive dynamic reflects confidence in Astex's pipeline and its positioning in an expanding sector, steering towards a scenario of consolidation and gradual valuation.

Analysis performed yesterday

Similar stocks to Astex Pharmaceuticals

Was this page helpful?

Your feedback helps us improve our research.

Take control
of your investments

Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.

  • Real-time multi-portfolio tracking
  • AI analysis of your positions
  • Counter your cognitive biases
Anantys Invest on iPhone